AOD9604
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- AOD9604
- DrugBank Accession Number
- DB06388
- Background
AOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 1815.1
Monoisotopic: 1813.860359661 - Chemical Formula
- C78H123N23O23S2
- Synonyms
- L-PHENYLALANINE, L-TYROSYL-L-LEUCYL-L-ARGINYL-L-ISOLEUCYL-L-VALYL-L-GLUTAMINYL-L-CYSTEINYL-L-ARGINYL-L-SERYL-L-VALYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-SERYL-L-CYSTEINYLGLYCYL-, CYCLIC (7->14)-DISULFIDE
- TYR-LEU-ARG-ILE-VAL-GLN-CYS-ARG-SER-VAL-GLU-GLY-SER-CYS-GLY-PHE CYCLIC (7->14)-DISULFIDE
Pharmacology
- Indication
Investigated for use/treatment in obesity and osteoporosis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
AOD9604 is a 16-amino acid, orally active peptide modelled on one fragment of the human Growth Hormone molecule. Studies suggest that AOD9604 retains the bone stimulating properties of human Growth Hormone. AOD9604 indicates that this drug may have a role in the prevention and possible treatment of osteoporosis, through direct action on osteoblasts, the cells which build new bone.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7UP768IP4M
- CAS number
- 221231-10-3
- InChI Key
- GVIYUKXRXPXMQM-BPXGDYAESA-N
- InChI
- InChI=1S/C78H123N23O23S2/c1-9-41(8)62(101-68(115)47(18-14-28-86-78(83)84)91-69(116)50(29-38(2)3)95-63(110)45(79)30-43-19-21-44(104)22-20-43)75(122)100-61(40(6)7)74(121)94-49(23-25-56(80)105)67(114)98-55-37-126-125-36-54(65(112)88-32-57(106)89-51(76(123)124)31-42-15-11-10-12-16-42)97-70(117)52(34-102)90-58(107)33-87-64(111)48(24-26-59(108)109)93-73(120)60(39(4)5)99-71(118)53(35-103)96-66(113)46(92-72(55)119)17-13-27-85-77(81)82/h10-12,15-16,19-22,38-41,45-55,60-62,102-104H,9,13-14,17-18,23-37,79H2,1-8H3,(H2,80,105)(H,87,111)(H,88,112)(H,89,106)(H,90,107)(H,91,116)(H,92,119)(H,93,120)(H,94,121)(H,95,110)(H,96,113)(H,97,117)(H,98,114)(H,99,118)(H,100,122)(H,101,115)(H,108,109)(H,123,124)(H4,81,82,85)(H4,83,84,86)/t41-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,60-,61-,62-/m0/s1
- IUPAC Name
- SMILES
- [H][C@](N)(CC1=CC=C(O)C=C1)C(\O)=N\[C@@]([H])(CC(C)C)C(\O)=N\[C@@]([H])(CCCNC(N)=N)C(\O)=N\[C@]([H])(C(\O)=N\[C@@]([H])(C(C)C)C(\O)=N\[C@@]([H])(CCC(O)=N)C(\O)=N\[C@@]1([H])CSSC[C@]([H])(\N=C(O)\[C@]([H])(CO)\N=C(O)/C\N=C(O)/[C@]([H])(CCC(O)=O)\N=C(O)\[C@@]([H])(\N=C(O)\[C@]([H])(CO)\N=C(O)/[C@]([H])(CCCNC(N)=N)\N=C1/O)C(C)C)C(\O)=N\C\C(O)=N\[C@@]([H])(CC1=CC=CC=C1)C(O)=O)[C@@]([H])(C)CC
References
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at March 19, 2008 16:28 / Updated at August 08, 2024 23:11